In recent years, the landscape of mental health treatment has witnessed a paradigm shift, with the resurgence of interest in psychedelic and ketamine-based therapies. These groundbreaking treatments offer promising results for individuals suffering from a range of mental health disorders, including depression, anxiety, and post-traumatic stress disorder (PTSD). Key players in this therapeutic revolution are drug development platform companies, like Alto Neuroscience, Beckley Psytech, atai Life Sciences, Bright Minds Biosciences, and Delix Therapeutics.